Marc beer is an entrepreneur with experience in pharmaceutical, Biotechnology and diagnostic markets. He holds a bachelor of science from the Miami University in Ohio. He is also the co-founder of Renovia group. He serves as a member of the Notre Dame Research and commercialization advisory board. He is also a member of the Miami University Business Advisory Council and the University’s Graduate Studies Research and Advisory committee.
His excellent leadership qualities and innovations enable him to practice business deals that assist people as he is committed to excelling in these businesses. He has created jobs to more than 300 people. He has guided companies that have since been listed in NASDAQ as well as going public.
Just recently Marc Beer was appointed as the chairman of the LumeNXT board. LumeNXT is a private company doing business with the aim of developing proprietary surgical lighting artifacts for simple persistent surgeries. He has over twenty-five years of experience in this industry thus suited for the new appointment as a chairman. LumeNXT boasts of engineers and surgeons that are experienced in the area of surgical illumination. Illumination increases precision, visibility, and flexibility during the surgical operation thus making the innovation helpful in comparison to customary techniques.
The technology offers a platform where illumination is used as a temperature reduction method to enhance surgical accuracy at an affordable cost and ensuring there is enough safety. Marc Beer is tasked with the duty of guiding the LumeNXT Company into positive growth and leading it to worldwide commercial rollout. His also tasked to make sure the company goes into big profits as it grows steadily.
LumeNXT original outlook protects tissues against damage to any high temperatures by incessantly eradicating the heat from the light giving elements. This technology has been of great help to the surgeons as it is more efficient. The company is dedicated to coming up with modified and individualized solutions that are based on values that the customer upholds.
He has also been at the helm of Minerva Neurosciences Company as the chairman of the board. It is a biopharmaceutical company developing products that treat diseases associated with the central nervous system. Before joining Minerva he held positions in the biopharmaceutical industry where he was tasked with launches which were commercial in nature looking into rare diseases in the world, worldwide growth, acquisitions, and IPOs.
Some of Marc Beer such position as a top executive includes the board o Good Start Genetics as its founding chairman, The CEO of Aegerion Pharmaceuticals, CEO of ViaCell, Vice President of Global Marketing at Genzyme as well as the Biotechnology Industry Organization Governing committee. Learn more: https://www.businesswire.com/news/home/20180821005199/en/Renovia-Completes-42.3-Million-Series-Financing